WuXi AppTec (603259) Stock Price, Fundamentals & Analysis

What 603259 does

WuXi AppTec (603259) is an investment holding company that provides research and manufacturing services to discover, develop, and manufacture small-molecule drugs across China, the United States, Europe, and other international markets. It operates through segments including WuXi Chemistry, WuXi Testing, and WuXi Biology, offering contract research, development, and manufacturing organization (CDRMO) services that cover the full lifecycle of new drug development, from target discovery through clinical trials and commercial manufacturing. The company also provides laboratory testing services such as toxicology, DMPK, and bioanalytical services, as well as clinical contract research organization services spanning Phase I to Phase IV studies.

Key numbers explained

• 162.4 CNY is the current price per share, representing the market's latest valuation of one unit of ownership.
• The trailing P/E ratio of 22 compares the share price to the last 12 months of earnings per share (7.37 CNY), showing how much investors pay for each yuan of recent profit.
• The forward P/E ratio of 17.2 uses expected future earnings, offering a view of valuation based on analyst estimates rather than past results.
• A dividend yield of 1.29% indicates the annual dividend payment as a percentage of the current share price, with 26% of earnings paid out as dividends.
• The beta of 0.49 suggests the stock has historically moved about half as much as the broader market in percentage terms, indicating lower volatility relative to the market.
• Market capitalization of 492.87B CNY reflects the total market value of all outstanding shares, placing the company among large-cap stocks.
• Revenue of 51.52B CNY over the trailing 12 months shows the scale of the company's business activity.
• Profit margin of 42.3% and operating margin of 43.3% indicate strong profitability relative to revenue and operating costs.

What to watch

WuXi AppTec operates in the Healthcare sector, specifically Diagnostics & Research, and is part of the Shanghai Stock Exchange stocks universe. Investors often monitor how its CDRMO business responds to global pharmaceutical R&D spending cycles and regulatory changes in drug approval processes. The stock's relatively low beta of 0.49 may appeal to those seeking less volatile exposure, though it also means the stock may lag in strong bull markets. As a large-cap holding with 492.87B CNY market capitalization, it is a core component of indices such as the CSI 300, meaning index rebalancing and foreign capital flows into Chinese equities can affect its price. Peer companies like Jiangsu Hengrui Medicine (600276), United Imaging (688271), BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE (603392), Guangzhou Baiyunshan Pharmaceutical Holdings (600332), Zhangzhou Pientzehuang Pharmaceutical (600436), Beijing Tongrentang (600085), and Shanghai Pharmaceuticals Holding (601607) provide context for sector comparisons.

FAQ

Q: Does 603259 pay a dividend? A: Yes, WuXi AppTec pays a dividend with a yield of 1.29%, and 26% of its earnings are distributed to shareholders.

Q: What is the 603259 P/E ratio? A: The trailing P/E ratio is 22, while the forward P/E ratio based on expected earnings is 17.2.

Q: Where can I buy 603259? A: WuXi AppTec trades on the Shanghai Stock Exchange under the symbol 603259.

Q: How volatile is 603259 compared to the market? A: With a beta of 0.49, the stock has historically been less volatile than the broader market.

Q: What is the 52-week price range for 603259? A: The lowest and highest prices in the last 52 weeks were 87.09 CNY and 173.6 CNY, respectively.

Q: How large is WuXi AppTec by revenue? A: Its trailing 12-month revenue is 51.52B CNY, reflecting its substantial scale in the healthcare services sector.